The production of mRNA vaccines in the COVID-19 pandemic: advent of new applications in health treatments
DOI:
https://doi.org/10.34119/bjhrv6n3-318Keywords:
mRNA, vaccine technology, COVID-19, applicationsAbstract
Modern vaccines developed using mRNA technology are highly accurate formulations designed to stimulate the production of a variety of antigenic properties in the user in order to activate adaptive immunity. This enables the use of such technology in the research of vaccines against several infectious diseases, such as hepatitis C, Acquired Immunodeficiency Syndrome (AIDS), malaria, tuberculosis, in addition to chronic diseases, such as some types of cancer. Such vaccines were an efficient alternative in the fight against COVID-19 and have remarkable characteristics, such as the versatility of their applications and the ability to encode and express virtually any type of protein. Like this, this work is justified by the need to know the potential applications of this technology in clinical practice and in the search for effective alternative solutions in the fight against infectious and chronic diseases. A systematic review of the literature was carried out, including texts in Portuguese or English from 2019 to the present day and original texts published before 2019, searched in databases such as Science Direct, US National Library of Medicine, Scielo, Pubmed and Instituto Nacional de Industrial Property (INPI).
References
Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-Based Vaccines. Vaccines; 2021,9,390.
Samagra J., Cho H., Singh S., Fischer SK, Hossain MA, & Sheikh, A. (2021). MRNA-based vaccines: past, present and future directions in the context of the COVID-19 pandemic. Elsevier BV, 2021.
Mayor A. The Poison King: The Life and Legend of Mithradates, Rome's Deadliest Enemy. Princeton University Press; 2009.
Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022 Mar 17;7(1):94. doi: 10.1038/s41392-022-00950-y. PMID: 29507924; PMCID: PMC9034996
Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020 Jun;65:14-20. doi: 10.1016/j.coi.2020.01.008. Epub 2020 Feb 6. PMID: 32035747.11.
Toledo Jr. ACC. Smallpox history. Rev Med Minas Gerais. 2005;15(1):58-65.
Cheng, L. & Hill, A. F. Therapeutically harnessing extracelular vesicles. Nat. Rev. Drug Discov. 21, 379–399 (2022).
Weng Y, Huang Y. Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins. Asian J Pharm Sci. 2021 Mar;16(2):263-264. doi: 10.1016/j.ajps.2021.02.005. Epub ahead of print. PMID: 33613906; PMCID: PMC7840764.
Szabó GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: Platforms and current developments. Mol Ther. 2022 Mar;30(3):785-798. doi: 10.1016/j.ymthe.2022.02.016. Epub 2022 Feb 17. PMID: 35091529.
Zeng C, Zhang C, Walker PG, Dong Y. Technologies for mRNA vaccine formulation and delivery. Top Current Topics in Microbiology and Immunology. 2020.
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012 Nov;9(11):1319-1330. doi: 10.4161/rna.22269. Epub 2012 Oct 23. PMID: 23095834; PMCID: PMC3554346.
Chakraborty, C., Sharma, AR, Bhattacharya, M., Sharma, G., Lee, SS, & Agoramoorthy, G. From COVID-19 to Cancer Vaccines: Moving from the bench to the clinic in the vaccine landscape. Frontiers in Immunology, 12, 720197. 2021.
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [Internet]. Geneva: World Health Organization; 2020 [cited 2022 Mar 26]. Available from:https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march- 2020
World Health Organization (WHO) (2021). Brasil. Recuperado em 22 de março de 2023, de https://www.who.int/
Costa DCA, Santos BDP, Albuquerque A. Public and private supply of beds and access to health care in the Covid-19 pandemic in Brazil. Health in Debate. 2020 [accessed on March 23, 2023];44(spe4):232-47. Available in:https://doi.org/10.1590/0103-11042020E415. printed version ISSN 2358-2898.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomedica: Atenei Parmensis. 2020;91(1):157-60. DOI: 10.23750/abm.v91i1.9397.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020; 383:2603-15,2020.
Jones B, Smith S, Brown A, Johnson K, Garcia M, Davis R, Lee C, Miller J. Synthetic mRNA vaccines. Journal of Clinical Investigation. 2021;131(5):e149621.
Thompson, MG, et al. (2020). Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — Eight US locations, December 2020–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(13), 495–500.
Smith CC, Miller TM, Yen L, Parekh DS, Kanabar P, Sharma S. mRNA delivery: a new path to genetic medicine. Journal of Biomolecular Techniques. 2019;30(1):43-53
Li L, Zhang Y, Li Y, Yu Y, Li M, Cao L. Advances in mRNA vaccine delivery. Nano Today. 2020;35:100962.
Wang Y, Yu R, Cui Z, Zhao J, Wen L, Huang J. Synthesis, purification, and quality control of mRNA. Methods in Molecular Biology. 2021;2183:3-22.
Kim DM, Rossi JJ. In vitro transcription for mRNA production. Methods in Molecular Biology. 2020; 2117:95-104.
Silva AL, Soares E, Machado M, Baptista P, Almeida A. Vaccines and mRNA therapeutics: a review of recent developments. Opinion of Experts in Biological Therapy. 2023;23(1):1-12.
Scorza F, Pardi N. New kids on the block RNA-based flu virus vaccines. Vaccines. 2018;6(2):20.
Brazzoli M., Magini D., Bonci A., Buccato S., Giovani C., Kratzer R., Stein DA Induction of broad-based immunity and protective efficacy by auto-mRNA vaccines amplifiers that encode influenza virus hemagglutinin. Journal of Virology, 90(1),332-344. 2016.
Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Pardi N. A single immunization with modified mRNA vaccines;2020.
Petsch, B., Mercurio, F., Schickli, J., O'malley, J., Newcomer, K., Mcguire, A., Felber, BK (2012). Protective efficacy of specific mRNA vaccines synthesized in vitro against influenza A virus infection. Nature Biotechnology, 30(12), 1210-1216.
Wang X, Zhang P. mRNA Vaccine - A Desirable Therapeutic Strategy to Overcome the COVID-19 Pandemic. Human and Immunotherapeutic Vaccines. 2022;18(3):579-580.
Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Smith M. Preclinical and clinical demonstration of immunogenicity of mRNA vaccines against influenza viruses H10N8 and H7N9. Molecular Therapy, 25(6), 1316-1327. 2017.
Kose N, Fox JM, Sapparapu G et al (2019) A lipid-encapsulated mRNA encoding a potent neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol 4:eaaw6647
Le T, Sun C, Chang J, Zhang G, Yin X. Development of mRNA vaccines for emerging animal and zoonotic diseases. Virus. 2022;14(3):401.
Pattnaik, A., Sahoo, BR, & Pattnaik, AK (2020). Current status of Zika virus vaccines: successes and challenges. Vaccines, vol.8, May 2020.
Richner, JM et al. Modified mRNA Vaccines Protect against Zika Virus Infection, Cell 168 (6) (2017) 1114–1125.e10,https://doi.org/10.1016/j.cell.2017.02.017.
Haynes Z, Cain BF. HIV mRNA Vaccines - Progress and Future Paths, & quot; Vaccines, Vol. 9, no. 2, Feb. 2021.
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Molecular Cancer. 2021;20(1).
Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of mRNA vaccine development. Nano Today. 2020;33:100874.
Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R(2019). Targeted Selection of HIV-Specific Antibody Mutations by B-Cell Maturation Engineering. Science. 366': eay
Kowalski PS, Rudra A, Miao L, Anderson DG. Clinical translation of vaccines and mRNA therapeutics. Nano Today. 2022; 40:101268.
Bee M, Koraka P, Osterhaus ADME. Dengue virus pathogenesis: an integrated view, Clin. Microbiol. Rev. 22 (4) (2009) 564–581, https://doi.org/10.1128/CMR.00035-09
Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for developing vaccines to control infectious diseases. Molecular Therapy. 2019;27(4):757-772.
Roth C., Cantaert T., Visser JC, Regner M., Schuessler-Langeheine S., Breitenbach A., Genton B. (2019). A modified mRNA vaccine targeting immunodominant epitopes protects against dengue virus infection in HLA class I transgenic mice. Frente in Immunology, vol.10, JUN 1-14,2019.
Schnee M., Altenhofen A., Voermanek D., Stamminger W., Roell T., Schirmer L., Kreek MJ An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Neglected Tropical Diseases, 10(6), 1-20, 2016.
Alberer M, Schwetye KE, Vesikari T, Wiedemann A, Zent O, Cho I, Reber J. Safety and immunogenicity of an mRNA rabies vaccine in healthy adults: a trial Open, non-randomized, prospective, first-in-human phase 1 clinical trial. The Lancet, 390 (10101), 1511-1520. 2017.
American Cancer Society. Cancer Treatment and Survival Facts and Figures 2022-2024. Atlanta: American Cancer Society; 2022. Available at: https://www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html. Accessed on: 24 Mar. 2023.
Amanpour, S. The rapid development and initial success of Covid-19 vaccines has raised hopes for accelerating the Cancer Treatment Facility. Arch Razi Inst. 2021;76(1):1-6.
Grabow WW, Jaeger L. RNA self-assembly and RNA nanotechnology. Acc Chem Res. 2014;47(6):1871-1880.
Tang Y, Zhao L, Yang Y, Yu S, Gao D (2021). Self-assembled small mRNA nanospheres for efficient therapeutic expression of apoptin and synergistic Gene Chemotherapy of breast cancer. Journal of Colloid and Interface Science, v. 603, p.191-198, Dec. 2021.
Camatta MW, Barroso RP. Theoretical comparative analysis between injectable collagen biostimulators. Rev. Bras Cir Plást. 2022;37(1):81-88.
Varani, J. et al. Decreased collagen production in chronologically aged skin: roles of age-dependent change in fibroblast function and defective mechanical stimulation. I am. J. Pathol.168, 1861–1868 (2006).
You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu WH, Liu Y, Chiang CL, Schrank BR, Huntoon K, Lee DY, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F, Kim BYS, Lee AS. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng [Internet]. 2023 Jan 12 [cited 2023 Mar 24];7(3):306-320. Available from: https://doi.org/10.1038/s41551-022-00840-3
Paunovska, K., Loughrey, D. & Dahlman, JE Drug delivery systems for RNA therapys. Nat. Rev. Genet.23, 265–280(2022).
Aldrich C, Magini D, Palmer S, Birch J, Riordan CR, Stein DA, Levandowski RA (2021). Proof of concept for a low dose unmodified mRNA-based mRNA rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vacina, 39(10), 1549-1556. 2021.
Cao, J., Lin, G., Zhang, Y., Chen, J., Zhou, H., & amp; Liang, G. mRNA therapy restores euglycemia and prevents liver tumors in a murine model of glycogen storage disease. Nature Communications, 12(1), 1-15. 2021.
Huang, Y., Zhang, H., Xie, L., He, Y., & Zhang, L. Intracellular delivery of mRNA to macrophages with surfactant-derived lipid nanoparticles. Materials Today Advances, 16, 100295. 2022.
Chen CY, Tran DM, Cavedon A, Cai X, Rajendran R, Lyle MJ, Miao CH. (2020). Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles. Molecular Therapy - Nucleic Acids, 20, 534–544. doi:10.1016/j.omtn.2020.03.015
Gupta G, Glueck R. NCOV-2019 Vaccine (SARS-COV-2). BR 112022016346-0 A2. 11/16/2022.
Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, Akili-Öztürk Ö, Kranz LM, Berger H, Petschenka J, Diken M, Kreiter S, Yogev N, Waisman A, Karikó K, Türeci Ö, Sahin U. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021 Jan 8;371(6525):145-153. doi: 10.1126/science.aay3638. PMID: 33414204
Shattock R, Blakney A, McKay P. RNA construct, nucleic acid sequence, expression cassette, recombinant vector, pharmaceutical composition, method for preparing RNA construct, vaccine, method for modifying a cell ex vivo or in vitro and modified cell. BR 112021024786-6 A2. National Publication Date: 02/22/2022. INPI.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Türeci Ö. The COVID-19 BNT162b1 vaccine elicits human and TH1 T cell responses. Nature. 2020;586(7830):594–9. https://doi.org/10.1038/s41586-020-2814-7.
